Health Care·Biotechnology·$28.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.72 | N/A | -16.50% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.72 | N/A | -16.50% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing clinical development despite the lack of financial guidance.
Management did not provide specific insights into revenue expectations.
The focus remains on advancing their clinical programs.
The earnings report indicates that Revolution Medicines is still in a development phase, with no revenue reported and a loss per share that missed expectations. The stock's decline of 2.76% reflects investor concerns about the lack of financial guidance and clarity on future performance. The company's focus on clinical programs suggests a longer-term strategy without immediate financial returns.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
US FOODS HLDG CORP
Nov 8, 2021